REFINED ALKALI TREATMENT OF NEPHROLITHIASIS

精碱治疗肾结石

• 批准号: 6238721
• 负责人: CHARLES Y.C PAK
• 金额: $ 15.14万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-14 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6238721
• 关键词: citrates; clinical trials; drug screening /evaluation; human subject; human therapy evaluation; hypercalciuria; hyperkalemias; kidney disorder chemotherapy; magnesium; nephrolithiasis; pharmacokinetics; phosphates; potassium; thiazide

The overall goals of this project are to determine whether (a) a special orthophosphate preparation (slow-release potassium phosphate or UroPhos-K) would produce physiological-physicochemical correction, inhibit stone formation, and provide safety of usage in absorptive hypercalciuria, and (b) a novel citrate formulation (potassium-magnesium citrate or K-Mag) would inhibit stone formation and provide safety of usage in patients with calcium stones. In Aim 1, we shall examine the effect of UroPhos-K on the crystallization of stone-forming salts while patients are kept on a constant metabolic diet. Aim 2, to commense upon satisfactory completion of Aim 1, will be a long-term randomized trial between UroPhos-K and placebo on stone formation. In Aim 3, we shall continue ongoing randomized trial between K-Mag and placebo on stone formation. Finally, Aim 4 will assess the value of K-Mag in preventing hypokalemia and magnesium depletion in patients taking thiazide for hypercalciuric nephrolithiasis. This project is biomedically important, since it could lead to the development of UroPhos-K as a rational and effective treatment of absorptive hypercalciuria, and of K-Mag as a superior drug over potassium citrate.

这个项目的总体目标是确定(a)一个特殊的